BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 25284366)

  • 21. Role of canine basal cells in prostatic post natal development, induction of hyperplasia, sex hormone-stimulated growth; and the ductal origin of carcinoma.
    Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
    Prostate; 2001 May; 47(3):149-63. PubMed ID: 11351344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer.
    Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Bostwick DG
    J Urol; 1999 Apr; 161(4):1229-32. PubMed ID: 10081875
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intensity of stromal changes predicts biochemical recurrence-free survival in prostatic carcinoma.
    Tomas D; Spajić B; Milosević M; Demirović A; Marusić Z; Kruslin B
    Scand J Urol Nephrol; 2010 Nov; 44(5):284-90. PubMed ID: 20459359
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease.
    Ricciardelli C; Choong CS; Buchanan G; Vivekanandan S; Neufing P; Stahl J; Marshall VR; Horsfall DJ; Tilley WD
    Prostate; 2005 Apr; 63(1):19-28. PubMed ID: 15378523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of canine basal cells in postnatal prostatic development, induction of hyperplasia, and sex hormone-stimulated growth; and the ductal origin of carcinoma.
    Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
    Prostate; 2001 Aug; 48(3):210-24. PubMed ID: 11494337
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inactivation of the p53 pathway in prostate cancer: impact on tumor progression.
    Osman I; Drobnjak M; Fazzari M; Ferrara J; Scher HI; Cordon-Cardo C
    Clin Cancer Res; 1999 Aug; 5(8):2082-8. PubMed ID: 10473090
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy.
    May M; Siegsmund M; Hammermann F; Loy V; Gunia S
    Scand J Urol Nephrol; 2007; 41(5):375-81. PubMed ID: 17853019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Limited pelvic lymph node dissection does not improve biochemical relapse-free survival at 10 years after radical prostatectomy in patients with low-risk prostate cancer.
    Weight CJ; Reuther AM; Gunn PW; Zippe CR; Dhar NB; Klein EA
    Urology; 2008 Jan; 71(1):141-5. PubMed ID: 18242383
    [TBL] [Abstract][Full Text] [Related]  

  • 29. KDM5C is overexpressed in prostate cancer and is a prognostic marker for prostate-specific antigen-relapse following radical prostatectomy.
    Stein J; Majores M; Rohde M; Lim S; Schneider S; Krappe E; Ellinger J; Dietel M; Stephan C; Jung K; Perner S; Kristiansen G; Kirfel J
    Am J Pathol; 2014 Sep; 184(9):2430-7. PubMed ID: 25016185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate cancer Ki-67 (MIB-1) expression, perineural invasion, and gleason score as biopsy-based predictors of prostate cancer mortality: the Mayo model.
    Tollefson MK; Karnes RJ; Kwon ED; Lohse CM; Rangel LJ; Mynderse LA; Cheville JC; Sebo TJ
    Mayo Clin Proc; 2014 Mar; 89(3):308-18. PubMed ID: 24486077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DNA-PKcs expression predicts response to radiotherapy in prostate cancer.
    Bouchaert P; Guerif S; Debiais C; Irani J; Fromont G
    Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1179-85. PubMed ID: 22494583
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Co-assessment of cytoplasmic and nuclear androgen receptor location in prostate specimens: potential implications for prostate cancer development and prognosis.
    Diallo JS; Aldejmah A; Mouhim AF; Fahmy MA; Koumakpayi IH; Sircar K; Bégin LR; Mes-Masson AM; Saad F
    BJU Int; 2008 May; 101(10):1302-9. PubMed ID: 18294307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery.
    Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Cheng L; Bostwick DG
    J Urol; 1999 Apr; 161(4):1233-7. PubMed ID: 10081876
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival.
    Cheville JC; Tindall D; Boelter C; Jenkins R; Lohse CM; Pankratz VS; Sebo TJ; Davis B; Blute ML
    Cancer; 2002 Sep; 95(5):1028-36. PubMed ID: 12209687
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
    Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI
    Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Different Growth Patterns of Canine Prostatic Carcinoma Suggests Different Models of Tumor-Initiating Cells.
    Akter SH; Lean FZ; Lu J; Grieco V; Palmieri C
    Vet Pathol; 2015 Nov; 52(6):1027-33. PubMed ID: 25755134
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation of androgen receptor status, neuroendocrine differentiation and angiogenesis with time-to-biochemical failure after radical prostatectomy in clinically localized prostate cancer.
    Revelos K; Petraki C; Scorilas A; Stefanakis S; Malovrouvas D; Alevizopoulos N; Kanellis G; Halapas A; Koutsilieris M
    Anticancer Res; 2007; 27(5B):3651-60. PubMed ID: 17972531
    [TBL] [Abstract][Full Text] [Related]  

  • 38. INPP4B restrains cell proliferation and metastasis via regulation of the PI3K/AKT/SGK pathway.
    Chen Y; Sun Z; Qi M; Wang X; Zhang W; Chen C; Liu J; Zhao W
    J Cell Mol Med; 2018 May; 22(5):2935-2943. PubMed ID: 29516642
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dysregulated PI3K/Akt/PTEN pathway is a marker of a short disease-free survival in node-negative breast carcinoma.
    Capodanno A; Camerini A; Orlandini C; Baldini E; Resta ML; Bevilacqua G; Collecchi P
    Hum Pathol; 2009 Oct; 40(10):1408-17. PubMed ID: 19428048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.